Platelet nitric oxide synthase is activated by tyrosine dephosphorylation: Possible role for SHP-1 phosphatase

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2423-2432

  Patel, B ^a   Sharifi, M ^a   Milward, A D ^a   Oberprieler, N G ^a   Gibbins, J M ^b   Parkin, S ^a   Naseem, Khalid M ^a,b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Nitric oxide synthase; Platelets; SHP 1

Indexed keywords

BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; RECOMBINANT ENZYME; THROMBIN; TYROSINE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME REGULATION; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD PLATELETS; BRADYKININ; CATTLE; ENZYME ACTIVATION; HEMOSTATICS; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; SHP1 PROTEIN TYROSINE PHOSPHATASE; THROMBIN; TYROSINE; VASODILATOR AGENTS;

EID: 33750053256     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02160.x     Document Type: Article

References (33)

1. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005; 26: 33-65.
2. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100: 350-6.
3. Ikeda H, Takajo Y, Murohara T, Ichiki K, Adachi H, Haramaki N, Katoh A, Imaizumi T. Platelet-derived nitric oxide and coronary risk factors. Hypertension 2000; 35: 904-7.
4. Shaul PW. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu Rev Physiol 2002; 64: 749-74.
5. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-8.
6. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′, 5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-55.
7. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996; 93: 1480-5.
8. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-12.
9. Fleming I, Bauersachs J, Fisslthaler B, Busse R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ Res 1998; 82: 686-95.
10. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 1995; 57: 2049-55.
11. Wallerath T, Gath I, Aulitzky WE, Pollock JS, Kleinert H, Forstermann U. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost 1997; 77: 163-7.
12. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 1995; 125: 370-7.
13. Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci 1994; 55: 1815-21.
14. de Belder A, Radomski M, Hancock V, Brown A, Moncada S, Martin J. Megakaryocytes from patients with coronary atherosclerosis express the inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 1995; 15: 637-41.
15. Radomski MW, Palmer RM, Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87: 5193-7.
16. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 2003; 90: 863-71.
17. Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. Thromb Res 2004; 114: 265-73.
18. Riba R, Sharifi M, Farndale RW, Naseem KM. Regulation of platelet guanylyl cyclase by collagen: Evidence that glycoprotein-VI mediates platelet nitric oxide synthesis in response to collagen. Thromb Haemost 2005; 94: 395-403.
19. Vargas JR, Radomski M, Moncada S. The use of prostacyclin in the separation from plasma and washing of human platelets. Prostaglandins 1982; 23: 929-45.
20. Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol 1989; 169: 3-11.
21. Barry FA, Gibbins JM. Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem 2002; 277: 12874-8.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
23. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 1996; 271: 27237-40.
24. Chiang TM, Woo-Rasberry V, Cole F. Role of platelet endothelial form of nitric oxide synthase in collagen-platelet interaction: Regulation by phosphorylation. Biochim Biophys Acta 2002; 1592: 169-74.
25. Lopez F, Ferjoux G, Cordelier P, Saint-Laurent N, Esteve JP, Vaysse N, Buscail L, Susini C. Neuronal nitric oxide synthase: A substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signalling. FASEB J 2001; 15: 2300-2.
26. Cordelier P, Esteve JP, Rivard N, Marletta M, Vaysse N, Susini C, Buscail L. The activation of neuronal NO synthase is mediated by G-protein betagamma subunit and the tyrosine phosphatase SHP-2. FASEB J 1999; 13: 2037-50.
27. Dixit M, Loot AE, Mohamed A, Fisslthaler B, Boulanger CM, Ceacareanu B, Hassid A, Busse R, Fleming I. Gab1, SHP2, and protein kinase A are crucial for the activation of the endothelial NO synthase by fluid shear stress. Circ Res 2005; 97: 1236-44.
28. Fulton D, Church JE, Ruan L, Li C, Sood SG, Kemp BE, Jennings IG, Venema RC. Src kinase activates endothelial nitric-oxide synthase by phosphorylating Tyr-83. J Biol Chem 2005; 280: 35943-52.
29. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001; 88: E68-75.
30. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001; 276: 17625-8.
31. Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001; 276: 16587-91.
32. Seo DW, Li H, Qu CK, Oh J, Kim YS, Diaz T, Wei B, Han JW, Stetler-Stevenson WG. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 2006; 281: 3711-21.
33. Krotz F, Engelbrecht B, Buerkle MA, Bassermann F, Bridell H, Gloe T, Duyster J, Pohl U, Sohn HY. The tyrosine phosphatase, SHP-1, is a negative regulator of endothelial superoxide formation. J Am Coll Cardiol 2005; 45: 1700-6.